News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diamyd Medical AB Broadens Diabetes Pipeline With Acquisition Of Nurel Therapeutics, Inc.


12/13/2005 3:31:39 PM

Diamyd Medical AB (OMX:DIAMB) emerged as a global biotechnology company as shareholders approved the acquisition of Nurel Therapeutics, Inc. at a General Assembly Meeting in Stockholm yesterday. The Pittsburgh, PA- based biotech adds significantly to Diamyd Medical's pipeline for diabetes which now includes both a therapeutic vaccine for autoimmune type 1 and type 2 diabetes as well as therapies for diabetic pain. The merger is expected to close on Friday, December 16.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES